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Oral cancer is one of the most common malignancies worldwide.
Although squamous cell carcinoma (SCC) contributes to over 90%
of all malignant tumours of the oral cavity, there is no relative tool
to identify cells possessing the cancerous phenotype within a
normal squamous cell population. 
It has been generally accepted that loss of function of the
tumour suppressor gene(s) (TSG) is a key event during the
progression of human malignancies (Fearon, 1998). Investigators
have identified genetic alterations associated with oral squamous
cell carcinomas (OSCCs), such as mutations in the p53 gene
(Chiba et al, 1996), the APC gene (Largery et al, 1994; Uzawa
et al, 1994), and mutation or hypermethylation of the p16 gene
(Heinzel et al, 1996; Miracca et al, 1999), as well as allelic imbal-
ances including genetic instability (Ishwad et al, 1995; Ogawara 
et al, 1998) and loss of heterozygosity (LOH) on several chromo-
somes (Maestro et al, 1993; Uzawa et al, 1996; Wu et al, 1997;
Wang et al, 1999). In addition, previous allelotyping studies of
human head and neck SCC (HNSCC) have shown multiple chro-
mosomal regions in which LOH frequently was observed (Ah-See
et al, 1994; Field et al, 1996; Scully and Field, 1997). This
evidence indicates that there are a number of TSGs involved in the
carcinogenesis of HNSCC, including OSCC. 
In simple allelotype studies, LOH at a marker on 21q was
observed in 37% of oesophageal SCCs (Aoki et al, 1994) and in
50% of SCCs of the lung (Sato et al, 1994). Our deletion mapping
study demonstrated that at least 3 distinct TSGs associated with
OSCCs may be harboured on 21q (Yamamoto et al, 1999).
Recently, a candidate TSG, abundant in neuroepithelium area gene
(ANA), was identified and mapped to 21q11.2–q21.1 (Yoshida 
et al, 1998). In the same study, homozygous deletion of the ANA
gene was found in a human non-small cell lung carcinoma
(NSCLC), whereas no mutation of the gene was detected in
primary NSCLCs. Given the high frequency of LOH in this
region, we hypothesized that the ANA gene is one of the target
genes for the development of human OSCC. 
In the current study, we performed a polymerase chain reaction
(PCR)-based LOH assay in the region spanning the ANA locus,
PCR-single strand conformational polymorphism (PCR-SSCP)
analysis, direct DNA sequencing and reverse transcription-PCR
(RT-PCR) to examine the role of genetic alterations of the ANA
gene in OSCCs. In addition, the level of ANA gene mRNA expres-
sion in OSCC-derived cell lines treated with or without a DNA
methylating chemical (5-aza-2¢-deoxycytidine) was assessed to
determine if the transcriptional silencing of the gene is linked to
promoter hypermethylation. 
MATERIALS AND METHODS 
Tumour specimen preparation and DNA/RNA extraction 
63 pairs of tumour and corresponding normal oral mucosa speci-
mens were obtained at the time of surgical resection between 1995
and 1999 at Chiba University Hospital and Tokyo Dental College
Hospital. Informed consent was obtained from all patients and also
from the families of the patients. The resected tissues were divided
into 2 segments; one was frozen immediately after carefully
removal from the surrounding normal tissues and stored at –80˚C
until extraction of DNA or RNA, and the other was fixed in 
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10% formalin for pathologic diagnosis. Histopathologic diagnosis
was performed according to the International Classification of
Tumours (Wahi, 1971) by the Department of Pathology, Chiba
University School of Medicine. Clinicopathologic staging was
determined by the TNM staging system (Hermanek and Sobin,
1987). All patients had histologically confirmed SCC of the oral
cavity and the tumour samples for DNA extraction were checked
to ensure that they consisted of more than 80% tumour within the
specimens. Genomic DNAs were extracted from powdered frozen
tumour and corresponding normal tissues by proteinase K diges-
tion and phenol-chloroform extraction, and then precipitated with
ethanol (Maniatis et al, 1982). 
Total RNA was extracted from 20 pairs of primary OSCC
specimens and their adjacent normal epithelial tissues using an
SV Total RNA Isolation System (Promega, Madison, WI, USA)
according to the manufacturer’s protocol. Concentrations of DNA
or RNA were estimated by a spectrophotometric method. The
samples were stored at –80˚C until use. 
DNA analysis of microsatellite repeat polymorphism 
7 microsatellite markers flanking the ANA locus were used to test
for LOH. The primer sequences of the microsatellite repeat poly-
morphisms were obtained from the GenBank Sequence Database.
Primers were isotopically end-labelled with [g-32P]-adenosine
triphosphate (Amersham Pharmacia Biotech, Uppsala, Sweden),
and PCR amplification was carried out in a final volume of 10 ml
as described previously (Uzawa et al, 1996). PCR products from
tumour and corresponding control DNAs were loaded in parallel
on 5% polyacrylamide gel containing 7 M urea and visualized
by autoradiography. Duplicate examinations were performed to
confirm LOH on 21q. LOH for tumour DNA samples was
assessed by scanning densitometry and analysed by National
Institutes of Health (NIH) software (Image version 1.62, Dr. W.
Rasband, NIH, Bethesda, MD, USA). The intensities of the signals
in tumour DNA were compared with those of the corresponding
normal DNA. We used Fisher’s exact test to analyse for signific-
ance of differences in frequencies of LOH between TNM staging
and tumour differentiation. The accepted level was P < 0.05. 
PCR-SSCP and direct DNA sequence analyses 
To screen for sequence variations of the ANA gene among patients
with OSCC, PCR-SSCP analysis was performed as described
previously (Uzawa et al, 1995). Exons from 2 to 5 of the ANA gene
were amplified with the specific primers according to Kohno et al
(1998). Mobility shifted bands identified by SSCP analysis were
excised, eluted from the gels, and re-amplified by PCR using
the initial PCR primers. The PCR fragments were purified
and sequenced using a cycle-sequencing method as described
previously (Uzawa et al, 1995). 
Evaluation of mRNA expression of the ANA gene 
To create first-strand cDNA for the ANA gene, 1.5 mg of total RNA
was used for RT. The reaction was performed using a Ready-
To-Go T-Primed First-Strand Kit (Amersham Pharmacia Biotech).
A 10% portion of the cDNA was amplified by PCR. The specific
primers for the ANA gene were synthesized based on the previ-
ously published sequence (Yoshida et al, 1998). To amplify the
cDNA for the ANA gene (GenBank accession #D64110), the
primer sequences were: Ana-F1 5¢-GAATCACTATCCTCCTC-
CTGT- 3¢; Ana-R1 5¢- GATGGTTTGGCCCATCTAAC-3¢. 
cDNA preparations were done in the presence and absence of
RT, the latter acting as a control for contaminating genomic DNA
from which fragments of the pseudogene can be amplified with
these primers. PCR amplification of cDNA for the ANA gene was
performed in 12.5 ml of PCR Master Mix (Roche Molecular
Biochemicals, Mannheim, Germany), 1 ml of the cDNA obtained
from the RT reaction, 1 ml of each of the specific primers (0.5 mg
ml–1) described previously and 10.5 ml of water. After amplifica-
tion, an aliquot of the PCR product (271 bp length) was separated
on a 3% TAE-agarose gel, stained with ethidium bromide. The
density of the ethidium bromide-stained bands was quantitated
using NIH image software. The results were normalized as a ratio
of each specific mRNA signal to the glyceraldehyde-3-phosphate
dehydrogenase gene (GAPDH) signal within the same RNA
sample. The expression ratio of the tumour was divided by that of
corresponding normal tissue to obtain the gene conservation rate.
When the conservation rate of a given specimen was less than 1.0,
this denoted reduced gene expression. Reproducibility was
confirmed by processing all samples at least twice. 
Cell lines and cell culture 
The following OSCC-derived cell lines were analysed: SAS,
HSC-2, HSC-3, HSC-4, Ca9-22, Ho-1-u-1, Ho-1-N-1, SCC4
(obtained from Human Science Research Resources Bank, Osaka,
Japan), and OK-92 (established from carcinoma of the tongue in
our department). All OSCC-derived cell lines were grown in
RPMI-1640 medium with 10% fetal bovine serum and 50 units
ml–1 penicillin and streptomycin. When cells reached confluence,
they were washed twice in cold phosphate buffered saline (PBS)
and total RNA was isolated with the same kit used for OSCC
tumours. RT-PCR was performed to examine the state of ANA
gene expression as mentioned previously. 
5-aza-2¢-deoxycytidine treatment 
To assess re-activation of the gene expression, the cells were
treated with different concentrations (0 and 2 mM) of the DNA
methyltransferase inhibitor, 5-aza-2¢-deoxycytidine, as described
previously (Timmermann et al, 1998). On day 5, cells were
washed with PBS and grown for an additional 10 days without the
demethylating chemical. After that, the cells were harvested, and
total RNA was extracted and the expression of the ANA gene was
evaluated by the RT-PCR as described previously. 
RESULTS 
Deletion mapping around the ANA locus 
A deletion map flanking the ANA locus was created for 126 DNA
samples obtained from oral tumours and normal tissues (Figure 1).
Of 63 cases that were informative for at least 1 of the loci, 32
(50.8%) showed allelic deletions. The frequencies of LOH for the
7 markers are listed in Table 1. The most frequent allelic losses
were identified at markers D21S369 (37%) at 21q and D21S236 at
21q (38%). These microsatellite markers were mapped to the
centromeric region of the ANA locus (Table 1). The results of
LOH analyses in the 32 LOH-positive cases are summarized in the756 N Yamamoto et al 
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deletion map in Figure 1 and representative results are shown in
Figure 2. 
In addition, we compared our results with the clinicopathologic
factors. A number of sites displaying LOH at 21q could be
detected in early-stage lesions; the frequencies of LOH tended to
be higher in later clinical stages, but no statistical correlation 
was observed. Furthermore, we failed to detect any relation
between the number of deletions per specimen and the grade of
differentiation. 
Mutation status of the ANA gene 
By PCR-SSCP analysis, bands with altered mobility were detected
in 6 cases. Among them, 5 cases showed normal sequence poly-
morphisms with a single base change (GGA/GAA at codon 
40) (data not shown). In contrast, a single nucleotide substitution
from GAG to GCG at codon 25, resulting in an amino acid
replacement of glutamine with alanine, was found in tissue sample
21 (Figure 3). The tumour of this patient was aggressive and
classified as clinical stage IV. 
Frequency of decreased levels of ANA mRNA in
primary OSCCs and in OSCC-derived cell lines 
The expression levels of ANA mRNA were examined in 20 paired
samples of primary OSCC tissues and matched adjacent normal
oral tissues, and in 9 OSCC-derived cell lines by RT-PCR analysis.
All normal tissues revealed a 271-bp ANA mRNA transcript,
which was the respective length of the PCR product. Among 20
cases tested, 12 oral tumours showed absent or significantly
reduced expression of the ANA gene (Table 2). The ANA gene
expression rate ranged from 0 to 0.25. Representative results are
summarized in Figure 4A. 11 of 12 tumours with suppressed ANA
gene expression were stage IV tumours. 8 of 9 cell lines had
Markers (locations)
D21S1433 (21q-p)
D21S369 (21q11.1)
D21S1231 (21q11.1)
D21S258 (21q11.1)
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D21S1256 (21q21)
D21S236 (21q11.1 )
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 2 3 2 4 2 5 2 6 2 7 2 8 2 9 3 0 3 1 3 2
Not informative
Retention of heterozygosity
Loss of heterozygosity
Microsatellite instability
Commonly deleted region
ANA
Tumours
Figure 1 A detailed deletion map of the area around the ANA locus in human OSCC. 32 cases showed LOH at one or more loci. The case number is shown
above each column, and 7 microsatellite markers are indicated on the left. 2 distinct commonly deleted regions are shown at markers D21S369 and D21S236 in
the centromeric location of the ANA locus 
Table 1 Loss of heterozygosity at 7 microsatellite regions on 21q in primary
OSCCs 
Marker Cytogenetic location Frequency of allelic loss (%)
(LOH / informative cases) 
Centromere ­
D21S1433 21p–q 15 (6/40) 
D21S369 21q11.1 37 (11/30) 
D21S1231 21q11.1 17 (5/30) 
D21S258 21q11.1 22 (11/50) 
D21S236 21q11.1 38 (18/48) 
D21S120 21q11.1–21 11 (3/28) 
ANA 21q11.2–21.1 – 
D21S1256 21q21 14 (7/50) 
Telomere     ¯LOH on 21q and ANA gene expression in oral cancer 757
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decreased  ANA mRNA expression compared to the average
expression level seen in 20 independently analysed normal oral
tissues (Figure 4B). 
Re-activation of ANA gene expression by the DNA
methyltransferase inhibitor (5-aza-2¢-deoxycytidine) 
Of the cell lines with reduced or absent ANA gene mRNA expres-
sion, 4 (SAS, HSC-4, Ca9-22, and OK-92) showed significantly
increased expression or re-expression of the gene after treatment
5-aza-2¢-deoxycytidine. It is noteworthy that these cells re-
activating ANA had a senescence-like state with significant 
up-regulation of the ANA gene. A representative result of OSCC-
derived cell line, HSC-4, is shown in Figure 5. 
DISCUSSION 
Allelic deletions on human 21q have been reported in several
types of human cancers, such as ovarian cancer (Cliby et al, 1993),
lung cancer (Sato et al, 1994; Kohno et al, 1998), oesophageal
cancer (Aoki et al, 1994), and renal cell carcinoma (Schwerdtle et
al, 1996). Recently, Sakata et al (1997) constructed a detailed dele-
tion map of 21q in stomach cancer and found 2 commonly deleted
regions at markers D21S1254 and D21S1456. More recently,
Ohgaki et al (1998) identified a commonly deleted region span-
ning 6 centi-morgans at 21q21 in breast cancer, which overlapped
the proximal commonly deleted region in gastric cancer. These
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Figure 4 RT-PCR analysis of freshly resected tissue samples (tumours, T;
corresponding normal tissues, N) for the ANA gene (A) and OSCC-derived
cell lines (B) (1, normal tissue; 2, SAS; 3, HSC-2; 4, HSC-3; 5, HSC-4; 6,
Ca9-22; 7, OK-92; 8, Ho-1-u-1; 9, Ho-1-N-1; 10, SCC-4). Each lower panel
indicates quantitation of the ANA gene RT-PCR products normalized to the
level of GAPDH mRNA 
7 21
N       T N       T
D21S236
Figure 2 Selection of tumours showing LOH (arrows) at 21q11.1 (D21S236
locus) (cases 7 and 21). Case numbers are shown above. N, corresponding
normal tissue; T, tumour tissue 
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Figure 3 Evidence for 2 mutational events in the ANA gene of a patient with
OSCC (case 21). Left panel, PCR-SSCP analysis for exon 2 of the ANA
gene. Abnormality mobility shifts are evident in lane T (tumour) when
compared with lane N (normal tissue); right panel, identification of a
nucleotide substitution in the tumour DNA sample. The 25th codon in the
sample changed from GAG (glutamine) to GCG (alanine) 758 N Yamamoto et al 
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observations suggest that more than one TSG specific to several
types of human malignancies may exist on 21q. In our previous
study, 3 potential TSG loci were identified on 21q in OSCCs
(Yamamoto et al, 1999). Of them, the most frequently deleted
region was identified on 21q11.1, which is near the ANA gene
locus. In the present study, we extended these initial observations
and identified 2 novel commonly deleted regions that are distinct
from and centromeric to the ANA locus (Table 1, Figure 1).
Interestingly, these regions are clearly different from those of
commonly deleted regions identified in gastric or breast cancer.
Therefore, the data suggest that there may be new target genes at
21q11.1 and that the genes may be specifically associated with the
pathogenesis of human OSCCs. On the other hand, our failure to
find any correlation between 21q LOH and clinicopathologic char-
acteristics, such as tumour size, lymph node status, clinical stage,
and histologic grade, might suggest that inactivation of the
unknown TSGs on 21q is an early event in carcinogenesis in a
subgroup of OSCCs but with little or no influence on further
tumour progression. 
The ANA gene, mapped on human chromosome 21q11.2–q21.1,
is a member of an anti-proliferative gene family, based on the fact
that it can inhibit the proliferative activity in NIH3T3 cells
(Yoshida et al, 1998). A homozygous deletion of the gene was
found in a human non-small cell lung cancer cell line, suggesting
that the gene is a candidate TSG (Kohno et al, 1998). In our
previous study, frequent allelic loss was identified on chromosome
arm 21q21 that includes the ANA gene locus in primary OSCCs
(Yamamoto et al, 1999). Thus, we hypothesized that loss of func-
tion of the ANA gene could contribute to the tumorigenesis of
OSCC. Almost half of the oral tumours analysed in the present
study showed suppressed expression of the ANA gene (Table 2,
Figure 4A), suggesting that transcriptional silencing through the
gene expression might occur. However, an intragenic mutation of
the ANA gene was observed in only one advanced case, while
others showed no mutation affecting gene function (Figure 2). It
has been widely believed that 2 mutational hits (mutation and
LOH) are required for the inactivation of a TSG. However, there is
considerable recent evidence that abnormal methylation at the
promoters of TSGs is a novel mechanism for the suppression of
these genes activity, which is defined as a third pathway (Jones and
Table 2 Summary of the molecular status of the ANA gene and clinicopathologic features in primary OSCCs 
Tumour No. Tumour differentiation Stage Site ANA mRNA expression level 21q-LOH 
52 W II Tongue Normal LOH 
55 P II Tongue Normal ROH 
14 M II Buccal mucosa Normal LOH 
63 W IV Gingiva Normal NI 
56 W IV Tongue Reduced ROH 
57 M I Lip Normal ROH 
64 W IV Gingiva Reduced NI 
58 M IV Gingiva Normal ROH 
59 W I Tongue Normal ROH 
60 W III Tongue Negative ROH 
61 W IV Buccal mucosa Negative ROH 
25 W IV Gingiva Negative LOH 
30 P IV Tongue Negative LOH 
31 M III Tongue Reduced LOH 
32 W II Oral floor Normal LOH 
62 M III Tongue Negative ROH 
54 W IV Gingiva Negative ROH 
43 P IV Tongue Negative ROH 
49 M III Tongue Negative LOH 
45 W IV Gingiva Reduced ROH 
W, well-differentiated OSCC; M, moderately differentiated OSCC; P, poorly differentiated OSCC; LOH, loss of heterozygosity; ROH, retention
of heterozygosity; NI, not informative. 
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Figure 5 A representative results of re-activation of the ANA gene in
OSCC-derived cell line (HSC-4) after treatment with 5-aza-2¢-deoxycytidine.
The OSCC cell line was treated for 5 days with or without 2 mM 5-aza-2¢-
deoxycytidine and cultured for an additional 10 days without the
demethylating agent. Note that significant up-regulation of the ANA gene
mRNA and that induction of a senescence-like state is seen in 5-aza-2¢-
deoxycytidine treated HSC-4 cell line. GAPDH gene mRNA signal was used
for the internal control of the analysis. Original magnification 3400 LOH on 21q and ANA gene expression in oral cancer 759
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Laird, 1999). Therefore, we hypothesized that down-regulation of
the gene expression could be linked to this pathway. Because 
the promoter region of the ANA gene has not been identified, we
tested whether treatment with a demethylating agent (5-aza-2¢-
deoxycytidine) would lead to increased steady levels of the ANA
gene in OSCC-derived cell lines. The ANA gene was re-activated
in 4 of 8 OSCC-derived cell lines after treatment with the DNA
demethylation agent, which showed down-regulation of the gene
(Figure 5), indicating that the promoter region of these 4 cell lines
is highly methylated. Therefore, our results suggest that the ANA
gene might be silenced by an epigenetic mechanism involving
aberrant DNA methylation. It would be interesting to clarify the
methylation status in human OSCC in future investigations. In
addition, it is worthwhile to mention that down-regulation of the
ANA gene was observed more frequently in stage IV tumours than
in earlier stage tumours (Table 2), suggesting that the expression
of the ANA gene is associated with the progression of OSCC. 
In conclusion, our observations suggest that repression of ANA
gene expression frequently accompanies tumour development in
OSCC, while ANA mutation is very rare. In addition, the deletion
map generated by the present study has provided additional
evidence for the presence of new TSGs by showing novel LOH
sites at 21q11.1. However, whether the 21q-LOH and/or inactiva-
tion of the ANA gene could be an important predictor of prognosis
and disease outcome needs to be clarified by further molecular
epidemiologic studies. 
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